- Additional information
- Reviews (0)
CJC-1295 works especially well by the elongation of its half-life. GHRH, while achieving the same effects and results without CJC-1295, is readily discarded through the action of dipeptidyl amino peptidase IV, also known as DPP-IV. In essence, regular action of GHRH is subdued by a negative feedback loop process, leading to a short half-life of roughly 7 minutes, and limited plasma and insulin production. CJC-1295 quells DPP-IV, and therefore seems to lead to heightened activity.
In one study, performed on individuals ranging from 21 to 61 years old, CJC-1295 was observed in action. Through subcutaneous injection, both weekly and biweekly, the presence of CJC-1295 pointed towards higher levels of plasma and insulin within the subjects’ blood. This was observed at dosages of 30 to 60 micrograms per kilogram of body weight.
|Dimensions||12 × 31 × 23 in|